Comparative Pharmacology
Head-to-head clinical analysis: MIVACRON IN DEXTROSE 5 IN PLASTIC CONTAINER versus ROCURONIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIVACRON IN DEXTROSE 5 IN PLASTIC CONTAINER versus ROCURONIUM BROMIDE.
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER vs ROCURONIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine-mediated depolarization and muscle contraction.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking acetylcholine binding and inhibiting muscle contraction.
Initial IV bolus of 0.15-0.2 mg/kg (following succinylcholine) or 0.25 mg/kg (without succinylcholine) over 30-60 seconds. Maintenance infusion: 8-10 mcg/kg/min for continuous neuromuscular blockade during anesthesia.
0.6 mg/kg IV bolus for intubation; maintenance: 0.1-0.2 mg/kg IV bolus as needed or continuous infusion 5-10 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 minutes (0.03-0.05 h) due to rapid hydrolysis by plasma esterases; clinical duration is short, with recovery of neuromuscular function beginning within 5-10 minutes after bolus dose.
Terminal elimination half-life: 1.4-2.4 minutes (distribution half-life: 3-5 minutes); recovery index (25-75%): 12-16 minutes; clinical duration (dose-dependent): 30-45 minutes (0.6 mg/kg) to 70-90 minutes (1.2 mg/kg)
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of the dose; biliary/fecal elimination accounts for the remainder, primarily as metabolites via the liver.
Renal: 33% unchanged; Biliary/fecal: 33% (as parent and metabolite); Hepatic metabolism: ~10-20%; remainder: unknown
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker